CMPX logo

Compass Therapeutics, Inc.

CMPX
Healthcare|Biotechnology|US
$0.76
+0.07 (+10.84%)
DCF Value
$0.12
Tangible Book / Share
$0.89
Cash / Share
$0.96
Financing Filings (last 12 months)
1
Shelf registrations / offering prospectuses — latest Dec 30, 2025 (S-3). Possible dilution.

Upcoming Data Readouts (7)

Dec 2026
Est. completion
P1Non Small Cell Lung Cancer
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664n=85
May 2027
Est. completion
P1P2Metastatic Biliary Tract Cancer
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
NCT06548412n=50
Aug 2027
Est. completion
P2P3Biliary Tract Cancer
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
NCT05506943n=168
Apr 2028
Est. completion
P1Gastroesophageal Cancer (GC)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841n=70
Jun 2028
Est. completion
P3Major Depressive Disorder
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
NCT06247839n=20
Nov 2028
Est. completion
P2P3PTSD - Post Traumatic Stress Disorder
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
NCT07570654n=300
Jun 2029
Est. completion
P1P2Glioblastoma
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
NCT07392957n=54

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Nov 2025
P3
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940
Sep 2025
P2
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
NCT05733546

Recent Press Releases

Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 (PD-1 x VEGF-A Bispecific Antibody) at the SITC 2026 Annual Meeting
Nov 6, 2026 · GlobeNewsWire
Compass Therapeutics to Participate in Upcoming November Investor Events
Nov 2, 2026 · GlobeNewsWire
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
Oct 24, 2026 · GlobeNewsWire
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 14, 2026 · GlobeNewsWire
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Sep 22, 2026 · GlobeNewsWire

SEC Filings (64)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 22, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jul 1, 20268-KMaterial eventDocumentIndex
Jun 23, 20268-KMaterial eventDocumentIndex
Jun 11, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 5, 202610-QQuarterly reportDocumentIndex
May 5, 20268-KMaterial eventDocumentIndex
Apr 29, 2026ARSAnnual report to holdersDocumentIndex
Apr 29, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 29, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 27, 20268-KMaterial eventDocumentIndex
Mar 12, 2026S-8Employee stock planDocumentIndex
Mar 5, 202610-KAnnual reportDocumentIndex
Mar 5, 20268-KMaterial eventDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 21, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jan 7, 2026EFFECTDocumentIndex
Jan 6, 20268-KMaterial eventDocumentIndex
Dec 31, 2025DEL AMDocumentIndex
Dec 30, 2025S-3Shelf registrationDocumentIndex
Nov 14, 2025SC 13GPassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex
Nov 5, 20258-KMaterial eventDocumentIndex
Oct 29, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 21, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 18, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 15, 2025SC 13D/AActivist / 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2025SC 13GPassive 5%+ stakeDocumentIndex
Aug 13, 20258-KMaterial eventDocumentIndex
Aug 13, 2025424B5Offering prospectusDocumentIndex
Aug 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex